Albireo Pharma Inc (NASDAQ:ALBO) Expected to Post Quarterly Sales of $1.38 Million

Wall Street brokerages expect Albireo Pharma Inc (NASDAQ:ALBO) to announce $1.38 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Albireo Pharma’s earnings, with estimates ranging from $750,000.00 to $2.00 million. Albireo Pharma posted sales of $240,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 475%. The company is expected to issue its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $5.12 million for the current financial year, with estimates ranging from $3.32 million to $6.82 million. For the next year, analysts expect that the company will report sales of $21.40 million, with estimates ranging from $3.50 million to $36.09 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.35) EPS for the quarter, topping analysts’ consensus estimates of ($1.44) by $0.09. The company had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $1.11 million. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%.



ALBO has been the topic of a number of research reports. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Wedbush reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Albireo Pharma in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $62.00 price target on shares of Albireo Pharma in a report on Sunday, August 11th. Zacks Investment Research cut shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Finally, William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Monday, July 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $51.50.

A number of hedge funds have recently modified their holdings of ALBO. Aperio Group LLC bought a new stake in Albireo Pharma during the 2nd quarter valued at $42,000. Meeder Asset Management Inc. raised its holdings in Albireo Pharma by 796.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,026 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,800 shares during the period. JPMorgan Chase & Co. raised its holdings in Albireo Pharma by 27.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,836 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 614 shares during the period. Bank of America Corp DE raised its holdings in Albireo Pharma by 87.6% during the 4th quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 3,020 shares during the period. Finally, D. E. Shaw & Co. Inc. bought a new stake in Albireo Pharma during the 2nd quarter valued at $233,000. 73.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:ALBO traded down $0.73 during mid-day trading on Friday, reaching $22.85. The company had a trading volume of 49,974 shares, compared to its average volume of 50,593. The firm has a market cap of $294.66 million, a price-to-earnings ratio of -5.80 and a beta of 1.53. The company’s 50-day moving average price is $24.24 and its 200-day moving average price is $29.95. Albireo Pharma has a one year low of $19.10 and a one year high of $38.69.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: What is the strike price in options trading?

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.